Skip to content

Insider · CIK 0001878020

Brady W Dougan

director

Files at HUMA (Humacyte, Inc.). First filing Nov 20, 2024, latest Nov 21, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 1
$7,979 bought, $6.6M sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

HUMA: Humacyte, Inc.

HUMAOct 9, 2026 · close 0.41

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
18Weak
HUMAbuy 2
Humacyte, Inc.
$7,979
1,797 shares
+1%-
58Moderate
HUMAsell 2
Humacyte, Inc.
$6.6M
1,500,000 shares
-46%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jan 21, 2025HUMA
Humacyte, Inc.
AGrant or award
Stock Options (right to buy)derivativeindirect: By spouse
+1,130,311$0.00$01,130,311Jan 23, 2025
Dec 19, 2024HUMA
Humacyte, Inc.
AGrant or award
Stock Options (right to buy)derivativeindirect: By spouse
+525$0.00$02,625Dec 20, 2024
Nov 19, 2024HUMA
Humacyte, Inc.
POpen-market purchase
Common Stockindirect: By spouse
+1,797$4.44$7,979243,851Nov 21, 2024
Nov 18, 2024HUMA
Humacyte, Inc.
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-811,172$4.44$3.6M2,419,712Nov 20, 2024
Nov 19, 2024HUMA
Humacyte, Inc.
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-427,459$4.34$1.9M1,992,253Nov 20, 2024
Nov 20, 2024HUMA
Humacyte, Inc.
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-261,369$4.40$1.2M1,730,884Nov 20, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Brady W Dougan: insider trades and track record | InsiderTell